Adalimumab in treatment-resistant hidradenitis suppurativa following recurrence after extensive affected area excision

A review of biologies therapy

Michael Samycia, Alain Brassard

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Background: Hidradenitis suppurativa (HS) is characterized by chronic, suppurative abscesses, sinus tracts, and fistulas affecting the axilla, groin, and perianal region resulting from hyperkeratosis and occlusion of the terminal hair follicle. Objective: This report highlights the use of biologic agents for the treatment of recalcitrant HS. Method: We report on a 48-year-old male with a 15-year history of refractory perianal-inguinal-buttock HS who, despite receiving numerous surgical drainages and traditional medical treatmentfor HS, still had severe pain. After trialing etanercept and infliximab with methotrexate, the patient had marked improvement with adalimumab. Aliterature review of biologies therapywas also performed. Results: After trialing m any traditional therapies, we found that adalimumab appears to be the mosteffective treatment modalityfor our patient. A literature search revealed 53 articles on biologies therapy in HS. These articles are summarized. Discussion: Biologic agents have been shown to have variable results in the treatment of refractory HS. Enough lowgrade evidence has been accumulated to make the use of these agents suitable in HS. Until more clinical trials are performed on this topic, physicians should use clinical judgment when treating HS with biologic agents and be cautious by watching for significant adverse effects.

Original languageEnglish (US)
JournalJournal of Cutaneous Medicine and Surgery
Volume17
Issue numberSUPPL.1
StatePublished - Jul 1 2013
Externally publishedYes

Fingerprint

Hidradenitis Suppurativa
Recurrence
Biological Factors
Groin
Therapeutics
Buttocks
Axilla
Hair Follicle
Adalimumab
Methotrexate
Abscess
Fistula
Drainage
Clinical Trials
Physicians
Pain

ASJC Scopus subject areas

  • Dermatology
  • Surgery

Cite this

@article{5a513f7f79c44604b2bbfe896abcc892,
title = "Adalimumab in treatment-resistant hidradenitis suppurativa following recurrence after extensive affected area excision: A review of biologies therapy",
abstract = "Background: Hidradenitis suppurativa (HS) is characterized by chronic, suppurative abscesses, sinus tracts, and fistulas affecting the axilla, groin, and perianal region resulting from hyperkeratosis and occlusion of the terminal hair follicle. Objective: This report highlights the use of biologic agents for the treatment of recalcitrant HS. Method: We report on a 48-year-old male with a 15-year history of refractory perianal-inguinal-buttock HS who, despite receiving numerous surgical drainages and traditional medical treatmentfor HS, still had severe pain. After trialing etanercept and infliximab with methotrexate, the patient had marked improvement with adalimumab. Aliterature review of biologies therapywas also performed. Results: After trialing m any traditional therapies, we found that adalimumab appears to be the mosteffective treatment modalityfor our patient. A literature search revealed 53 articles on biologies therapy in HS. These articles are summarized. Discussion: Biologic agents have been shown to have variable results in the treatment of refractory HS. Enough lowgrade evidence has been accumulated to make the use of these agents suitable in HS. Until more clinical trials are performed on this topic, physicians should use clinical judgment when treating HS with biologic agents and be cautious by watching for significant adverse effects.",
author = "Michael Samycia and Alain Brassard",
year = "2013",
month = "7",
day = "1",
language = "English (US)",
volume = "17",
journal = "Journal of Cutaneous Medicine and Surgery",
issn = "1203-4754",
publisher = "Decker Publishing",
number = "SUPPL.1",

}

TY - JOUR

T1 - Adalimumab in treatment-resistant hidradenitis suppurativa following recurrence after extensive affected area excision

T2 - A review of biologies therapy

AU - Samycia, Michael

AU - Brassard, Alain

PY - 2013/7/1

Y1 - 2013/7/1

N2 - Background: Hidradenitis suppurativa (HS) is characterized by chronic, suppurative abscesses, sinus tracts, and fistulas affecting the axilla, groin, and perianal region resulting from hyperkeratosis and occlusion of the terminal hair follicle. Objective: This report highlights the use of biologic agents for the treatment of recalcitrant HS. Method: We report on a 48-year-old male with a 15-year history of refractory perianal-inguinal-buttock HS who, despite receiving numerous surgical drainages and traditional medical treatmentfor HS, still had severe pain. After trialing etanercept and infliximab with methotrexate, the patient had marked improvement with adalimumab. Aliterature review of biologies therapywas also performed. Results: After trialing m any traditional therapies, we found that adalimumab appears to be the mosteffective treatment modalityfor our patient. A literature search revealed 53 articles on biologies therapy in HS. These articles are summarized. Discussion: Biologic agents have been shown to have variable results in the treatment of refractory HS. Enough lowgrade evidence has been accumulated to make the use of these agents suitable in HS. Until more clinical trials are performed on this topic, physicians should use clinical judgment when treating HS with biologic agents and be cautious by watching for significant adverse effects.

AB - Background: Hidradenitis suppurativa (HS) is characterized by chronic, suppurative abscesses, sinus tracts, and fistulas affecting the axilla, groin, and perianal region resulting from hyperkeratosis and occlusion of the terminal hair follicle. Objective: This report highlights the use of biologic agents for the treatment of recalcitrant HS. Method: We report on a 48-year-old male with a 15-year history of refractory perianal-inguinal-buttock HS who, despite receiving numerous surgical drainages and traditional medical treatmentfor HS, still had severe pain. After trialing etanercept and infliximab with methotrexate, the patient had marked improvement with adalimumab. Aliterature review of biologies therapywas also performed. Results: After trialing m any traditional therapies, we found that adalimumab appears to be the mosteffective treatment modalityfor our patient. A literature search revealed 53 articles on biologies therapy in HS. These articles are summarized. Discussion: Biologic agents have been shown to have variable results in the treatment of refractory HS. Enough lowgrade evidence has been accumulated to make the use of these agents suitable in HS. Until more clinical trials are performed on this topic, physicians should use clinical judgment when treating HS with biologic agents and be cautious by watching for significant adverse effects.

UR - http://www.scopus.com/inward/record.url?scp=84885788328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885788328&partnerID=8YFLogxK

M3 - Review article

VL - 17

JO - Journal of Cutaneous Medicine and Surgery

JF - Journal of Cutaneous Medicine and Surgery

SN - 1203-4754

IS - SUPPL.1

ER -